ProCE Banner Activity

Evolving Role of Immunotherapy in Newly Diagnosed Advanced or Metastatic NSCLC

Slideset Download

Download these slides from a live CCO Webinar for a case-based overview of the optimal use of immunotherapy for the treatment of advanced or metastatic NSCLC, including first-line therapy decisions across the spectrum of PD-L1 expression levels and what to do after acquired resistance to checkpoint inhibition.

Released: June 24, 2021

Expiration: June 23, 2022

No longer available for credit.

Share

Faculty

Scott Gettinger

Scott Gettinger, MD

Professor of Internal Medicine (Medical Oncology)
Chief, Thoracic Medical Oncology
Yale Cancer Center
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Helsinn Healthcare SA

Regeneron Pharmaceuticals, Inc.

Sanofi Genzyme

Faculty Disclosure

Primary Author

Scott Gettinger, MD

Professor of Internal Medicine (Medical Oncology)
Chief, Thoracic Medical Oncology
Yale Cancer Center
New Haven, Connecticut